GNH USA

Europe — EMA

Lanreotidă Terapia (Lanreotide)

GNH USA supplies Lanreotidă Terapia (Lanreotide), a somatostatin analog for acromegaly and neuroendocrine tumors. Request a quote for global supply today.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Lanreotidă Terapia, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed in the management of acromegaly and somatostatin receptor‑positive neuroendocrine tumors, reducing excess hormone secretion and tumor growth.

GNH USA supplies Lanreotidă Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers benefit from reliable logistics and responsive technical support.

What is Lanreotide used for?

Lanreotide is a somatostatin analog used to control hormone‑driven conditions.

Acromegaly: reduces excess growth hormone levels and associated clinical features. Somatostatin receptor‑positive neuroendocrine tumors: inhibits tumor growth and hormone secretion. Carcinoid syndrome: alleviates flushing and diarrhea by suppressing serotonin release.

What are the side effects of Lanreotide?

Lanreotide may cause a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Diarrhea or abdominal discomfort - Nausea or vomiting - Headache - Mild hyperglycemia

Serious or Rare Side Effects: - Gallstone formation - Acute pancreatitis - Severe hyperglycemia or new‑onset diabetes - Allergic reactions including anaphylaxis - Cardiac arrhythmias

What precautions apply to Lanreotide?

Before initiating therapy, consider the following safety measures.

Pregnancy: consult a healthcare professional; safety data are limited. Breastfeeding: avoid unless the benefit outweighs potential risk to the infant. Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution and observe liver function tests. Blood glucose monitoring: watch for hyperglycemia, especially in diabetic patients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Lanreotide interact with?

Lanreotide can interact with other medicines; awareness helps manage risks.

Major Interactions (Avoid): - Octreotide: additive somatostatin effects may exacerbate glucose disturbances. - Strong CYP450 inhibitors: may alter the metabolism of co‑administered drugs.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: monitor blood glucose and adjust doses if needed. - Anticoagulants: observe for changes in bleeding tendency. - Thyroid hormone replacement: check thyroid function periodically.

Frequently asked questions

What is Lanreotidă Terapia used for?+
Lanreotidă Terapia contains lanreotide, a somatostatin analog indicated for the treatment of acromegaly, somatostatin receptor‑positive neuroendocrine tumors, and carcinoid syndrome. In these conditions it helps lower excessive hormone production and can slow tumor growth.
How does lanreotide work?+
Lanreotide binds selectively to somatostatin receptors SSTR2 and SSTR5 on endocrine and tumor cells. This binding blocks adenylate cyclase, reduces cyclic AMP levels, and suppresses the secretion of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease activity.
What is the usual dose of Lanreotidă Terapia?+
The dosage and administration schedule for Lanreotidă Terapia are determined by the prescribing physician based on the patient’s specific condition, disease severity, and response to therapy. The prescriber will set the appropriate dose and interval.
Is Lanreotidă Terapia safe during pregnancy or breastfeeding?+
Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.
How do I order Lanreotidă Terapia from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Lanreotidă Terapia compare with other somatostatin analogs?+
Lanreotide and octreotide are the two main long‑acting somatostatin analogs. Both target SSTR2 and SSTR5, but lanreotide is typically administered as a deep‑subcutaneous injection every 4–8 weeks, whereas octreotide may require more frequent dosing. Choice depends on physician preference, patient convenience, and individual response.
What are the storage and handling requirements for Lanreotidă Terapia?+
Lanreotidă Terapia should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.
How is Lanreotidă Terapia administered?+
The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional injects the prescribed volume deep into the subcutaneous tissue, usually in the abdomen or thigh, following aseptic technique. The injection schedule is set by the prescriber, often every 4 or 8 weeks.
What are the most serious risks associated with Lanreotidă Terapia?+
Serious adverse events include gallstone formation, acute pancreatitis, severe hyperglycemia or new‑onset diabetes, allergic reactions such as anaphylaxis, and cardiac arrhythmias. Patients should be monitored for abdominal pain, unexplained fever, changes in blood glucose, and any signs of hypersensitivity.
Who should not use Lanreotidă Terapia?+
Lanreotidă Terapia is contraindicated in patients with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or a history of gallbladder disease. The prescriber should evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Terapia S.A.
Origin
EU

Related products

Ipstyl

Ipstyl

Lanreotide

Ipsen S.P.A.
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Lanrenet

Lanrenet

Lanreotide

Mylan S.P.A.
EU